US Patent Office grants Trethera patent for compositions of matter
LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company focused on the development of novel drugs that target nucleotide